logo

WVE

Wave Life Sciences·NASDAQ
--
--(--)
--
--(--)
1.33 / 10
Underperform

WVE's fundamental evaluation is weak (1.3/10). Key positives include a healthy inventory turnover ratio (47.88) and strong interest coverage (15.51), but these are offset by subpar year-over-year revenue growth (3.78%) and overall profit metrics. The Net profit / Total profit ratio of 100% suggests full profit retention, yet the PB-ROE discrepancy (3.60) and negative asset-revenue MV differences indicate valuation and scale concerns. Historical factor tests show consistently negative monthly returns, reinforcing the cautious view.

Fundamental(1.33)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-3.02
Score1/3
Weight14.22%
1M Return3.98%
Total operating revenue (YoY growth rate %)
Value3.78
Score1/3
Weight-1.72%
1M Return-0.60%
Inventory turnover ratio
Value47.88
Score2/3
Weight-3.42%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight33.03%
1M Return8.99%
PB-ROE
Value3.60
Score0/3
Weight11.76%
1M Return3.36%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-3.56%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value3.78
Score1/3
Weight-1.50%
1M Return-0.52%
Asset-MV
Value-0.51
Score0/3
Weight22.31%
1M Return6.58%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-2.81%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight31.70%
1M Return8.80%
Is WVE fundamentally strong?
  • WVE scores 1.33/10 on fundamentals and holds a Premium valuation at present. Backed by its -86.45% ROE, -111.64% net margin, -20.47 P/E ratio, 18.85 P/B ratio, and 41.96% earnings growth, these metrics solidify its Underperform investment rating.